MX2009004763A - Moduladores aloestericos del receptor de adenosina a1. - Google Patents
Moduladores aloestericos del receptor de adenosina a1.Info
- Publication number
- MX2009004763A MX2009004763A MX2009004763A MX2009004763A MX2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine receptor
- formula
- allosteric modulators
- compounds
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (I), en donde R1, R2, R3, R4 y Q, tienen un significado como se define aquí en la especificación. Los compuestos de fórmula (I), son moduladores alostéricos del receptor de adenosina A1, y de este modo, pueden ser empleados para el tratamiento de condiciones mediadas por el receptor de adenosina A1. Por consiguiente, los compuestos de fórmula (I), pueden ser empleados para el tratamiento de dolor en particular, dolor crónico tal como dolor neuropático, enfermedad o trastorno cardiaco, tal como disaritmias cardiacas, por ejemplo, taquicardia supraventricular peroxismal, angina, infarto al miocardio y apoplejía, enfermedad o lesión neurológica, trastornos del sueño, epilepsia y depresión.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85850506P | 2006-11-13 | 2006-11-13 | |
US11/938,514 US7897596B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
US11/938,465 US7855209B2 (en) | 2006-11-13 | 2007-11-12 | Allosteric modulators of the A1 adenosine receptor |
PCT/US2007/084490 WO2008063984A2 (en) | 2006-11-13 | 2007-11-13 | Allosteric modulators of the a1 adenosine receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004763A true MX2009004763A (es) | 2009-05-21 |
Family
ID=39430473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004763A MX2009004763A (es) | 2006-11-13 | 2007-11-13 | Moduladores aloestericos del receptor de adenosina a1. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2081575A4 (es) |
JP (1) | JP2010509402A (es) |
KR (1) | KR20090112627A (es) |
AU (1) | AU2007323888A1 (es) |
BR (1) | BRPI0718520A2 (es) |
CA (1) | CA2669447A1 (es) |
IL (1) | IL198402A0 (es) |
MX (1) | MX2009004763A (es) |
WO (1) | WO2008063984A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739588B (zh) * | 2014-01-04 | 2015-07-01 | 新发药业有限公司 | 一种2-氨基噻吩衍生物的简便合成方法 |
US10434099B2 (en) | 2016-09-22 | 2019-10-08 | The National Institute for Biotechnology in the Negev Ltd. | Methods for treating central nervous system disorders using VDAC inhibitors |
AU2016325108B2 (en) * | 2015-09-14 | 2020-10-22 | The National Institute for Biotechnology in the Negev Ltd. | Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
US10787423B2 (en) | 2015-09-14 | 2020-09-29 | The National Institute For Biotechnolgy In The Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
EP3600290A4 (en) | 2017-03-21 | 2020-08-12 | Temple University - Of The Commonwealth System of Higher Education | NEW SIGMA 2 RECEIVER MODULATORS AND THEIR OPERATING PROCEDURE |
WO2018175190A1 (en) | 2017-03-21 | 2018-09-27 | Temple University-Of The Commonwealth System Of Higher Education | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5332732A (en) * | 1992-09-11 | 1994-07-26 | Mcneilab, Inc. | Thiophene and pyridine antipsychotic agents |
ES2092737T3 (es) * | 1992-10-29 | 1996-12-01 | Hoechst Ag | Procedimiento para la preparacion de compuestos bromometil-aromaticos. |
US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
-
2007
- 2007-11-13 KR KR1020097009765A patent/KR20090112627A/ko not_active Application Discontinuation
- 2007-11-13 EP EP07864306A patent/EP2081575A4/en not_active Withdrawn
- 2007-11-13 WO PCT/US2007/084490 patent/WO2008063984A2/en active Application Filing
- 2007-11-13 MX MX2009004763A patent/MX2009004763A/es not_active Application Discontinuation
- 2007-11-13 AU AU2007323888A patent/AU2007323888A1/en not_active Abandoned
- 2007-11-13 BR BRPI0718520-0A patent/BRPI0718520A2/pt not_active IP Right Cessation
- 2007-11-13 CA CA002669447A patent/CA2669447A1/en not_active Abandoned
- 2007-11-13 JP JP2009537305A patent/JP2010509402A/ja not_active Withdrawn
-
2009
- 2009-04-26 IL IL198402A patent/IL198402A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008063984A2 (en) | 2008-05-29 |
CA2669447A1 (en) | 2008-05-29 |
WO2008063984A3 (en) | 2008-08-14 |
BRPI0718520A2 (pt) | 2013-11-19 |
KR20090112627A (ko) | 2009-10-28 |
IL198402A0 (en) | 2010-02-17 |
EP2081575A4 (en) | 2010-01-06 |
EP2081575A2 (en) | 2009-07-29 |
AU2007323888A1 (en) | 2008-05-29 |
JP2010509402A (ja) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009004763A (es) | Moduladores aloestericos del receptor de adenosina a1. | |
UA103198C2 (en) | Squaramide derivatives as cxcr2 antagonists | |
MX2010001446A (es) | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. | |
TW200745037A (en) | Organic compounds | |
EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2009043889A3 (en) | Oxadiazole derivatives | |
WO2010045258A3 (en) | Spirocyclic gpr40 modulators | |
MX2010003614A (es) | Compuestos de diarilo oxadiazol. | |
PL2303330T3 (pl) | Kompozycje farmaceutyczne do leczenia choroby Parkinsona | |
MX2011006334A (es) | Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol. | |
IL209896A0 (en) | Compounds for treating symptoms associated with parkinson's disease | |
EA201001404A1 (ru) | Амиды 5-оксо-2,3,4,5-тетрагидробензо[b]оксепин-4-карбоновой кислоты и амиды 2,3-дигидробензо[b]оксепин-4-карбоновой кислоты для лечения и предотвращения диабета 1 и 2 типа | |
WO2007108936A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
SI2024368T1 (sl) | Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine | |
WO2010042925A3 (en) | Compositions and methods for treating alcohol use disorders, pain and other diseases | |
WO2007136668A3 (en) | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
WO2008045371A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
ATE520651T1 (de) | Substituierte phenylmethylbicyclocarbonsäureamidverbindungen | |
IL208732A (en) | Methods for producing morphogenetic protein of bones number 2 bmp | |
MA33190B1 (fr) | Composes pour le traitement de troubles metaboliques | |
EP2749554A3 (en) | 2,5-disubstituted arylsulfonamide CCR3 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |